8-K filed Jul 13, 2026 at 08:39 ET
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata. The mITT population (n=25) showed a 35.3% mean SALT reduction and 40.0% SALT-20 response, with no Grade 3 or higher adverse events and negligible anti-drug antibodies. The company plans to advance to a registration-directed program and engage the FDA in 1H27, supporting a differentiated biologic profile in a >$5B US market opportunity.